02171 科濟藥業－Ｂ
按盤價 
13.920 +3.050 (+28.059%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 資產回報率 (%) | -6.601% | -40.615% | -29.792% | -28.468% | -199.367% |
| 股東資金回報率 (%) | -10.637% | -55.845% | -34.986% | -32.624% | -718.562% |
| 資本運用回報率 (%) | -9.006% | -56.245% | -36.283% | -34.426% | -152.237% |
邊際利潤分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 63.621% | 37.405% | N/A | N/A | -- |
| 未計利息、稅項、折舊及攤銷前利潤率 (%) | -64.712% | -1913.598% | N/A | N/A | -18142.308% |
| 稅前邊際利潤率 (%) | -81.892% | -2023.554% | N/A | N/A | -18350.358% |
| 純利率 (%) | -77.876% | -2024.431% | N/A | N/A | -18379.975% |
變現能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流動比率 (X) | 5.734 X | 6.025 X | 9.546 X | 13.454 X | 7.891 X |
| 速動比率 (X) | 5.699 X | 5.997 X | 9.543 X | 13.454 X | 7.891 X |
財務槓桿分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 總負債 / 總資產比率 (%) | 39.686% | 36.839% | 20.180% | 10.484% | 14.519% |
| 總債項 / 總資產比率 (%) | 4.735% | 9.947% | 3.775% | 4.323% | 9.643% |
| 淨債項 / 總資產比率 (%) | -82.208% | -78.458% | -78.173% | -77.768% | -10.076% |
| 總債項 / 股東資金比率 (%) | 7.810% | 15.749% | 4.730% | 4.830% | 11.281% |
| 長期債項 / 股東資金比率 (%) | 6.171% | 12.557% | 3.911% | 3.941% | 3.493% |
| 淨債項 / 股東資金比率 (%) | -135.607% | -124.219% | -97.937% | -86.876% | -11.788% |
| 淨現金 / (債項) ($) | 10.62億 | 13.13億 | 17.65億 | 21.49億 | 3.53億 |
| 每股淨現金 / (債項) ($) | 1.863 | 2.296 | 3.065 | 3.752 | 0.622 |
| 總債項 / 資本運用比率 (%) | 5.630% | 11.728% | 4.135% | 4.609% | 10.847% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
營運效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存貨周轉率日數 (日) | 56.146日 | 56.270日 | -- | N/A | N/A |
| 應收貿易帳周轉率日數 (日) | 35.320日 | 81.175日 | N/A | N/A | N/A |
| 應付貿易帳周轉率日數 (日) | N/A | N/A | N/A | N/A | N/A |
| 備註： | 即時報價更新時間為09/03/2026 17:59 |
| 港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站 | |
| 股東應佔溢利/(虧損) (千) | RMB -97,861 |
| 增長率 | -87.739% |
| 每股盈利/(虧損) | RMB -0.180 |
| 每股帳面資產淨值 (¥) | RMB 1.374 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
